TGTX TG Therapeutics Inc.

INVESTOR ALERT: Goldberg Law PC Announces an Investigation of TG Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--

Goldberg Law PC announces that it is investigating TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (Nasdaq: TGTX) concerning possible violations of federal securities laws.

If you purchased or otherwise acquired TG Therapeutics shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at [email protected].

The investigation focuses on the October 13, 2016 press release that TG Therapeutics filed an amended protocol with the Food and Drug Administration for its leukemia drug combination, GENUINE Phase 3 Trial. The Company no longer benefits from its previously negotiated Special Protocol Assessment with the FDA.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at [email protected].

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
14/10/2016

Underlying

TGTXTG Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TG Therapeutics Inc.

 PRESS RELEASE
Free
TGTX TG Therapeutics...

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financi...

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update Conference Call to be Held Monday, August 4, 2025, at 8:30 am ET NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 4, 2025, at 8:30 AM ET to discuss results for the second quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407...

July 30, 2025 1 EN
 PRESS RELEASE
Free
TGTX TG Therapeutics...

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global...

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET. NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025. The fireside chat is scheduled to take place on Tuesday, June 10, 2025, at 10:40am ET. A live webcast of the fireside chat will be avail...

June 6, 2025 1 EN
 PRESS RELEASE
Free
TGTX TG Therapeutics...

TG Therapeutics to Participate in the Jefferies Global Healthcare Conf...

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference Fireside chat scheduled for Wednesday, June 4, 2025, at 12:50pm ET NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 3-5, 2025. The fireside chat is scheduled to take place on Wednesday, June 4, 2025, at 12:50 PM ET. A live webcast of the fireside chat will be availab...

June 2, 2025 1 EN
 PRESS RELEASE
Free
TGTX TG Therapeutics...

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple S...

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Links to each presentation are included below. “We were pleased to present three encore presentations yesterday during the CM...

May 30, 2025 1 EN
 PRESS RELEASE
Free
TGTX TG Therapeutics...

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® ...

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 28-31, 2025 in Phoenix, Arizona. Abstracts are now available online and can be accessed on the CMSC ...

May 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch